Selected first quarter approvals.

Company

Approval

Anika Therapeutics Inc. (NASDAQ:ANIK)/Johnson & Johnson (NYSE:JNJ)

FDA approves Monovisc to treat osteoarthritis of the knee

AstraZeneca plc (LSE:AZN; NYSE:AZN)

FDA approves Myalept metreleptin to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy

AstraZeneca plc (LSE:AZN; NYSE:AZN)/Ono Pharmaceutical Co. Ltd. (Tokyo:4528)

FDA approves Farxiga dapagliflozin as an adjunct to diet and exercise to improve glycemic control in Type II diabetics. Japan approves dapagliflozin as Forxiga to treat Type II diabetes

Bayer AG (Xetra:BAYN)

EC approves Adempas riociguat to treat pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH)

Biogen Idec Inc. (NASDAQ:BIIB)

EC approves Tecfidera dimethyl fumarate as first-line treatment for relapsing-remitting multiple sclerosis (RRMS)

Biogen Idec Inc. (NASDAQ:BIIB)/Swedish Orphan Biovitrum AB (SSE:SOBI)

Canada and FDA approve Alprolix for hemophilia B. Alprolix is a recombinant fusion protein consisting of human coagulation Factor IX attached to the Fc domain of human IgG1

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

FDA approves Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome)

Celgene Corp. (NASDAQ:CELG)

EC approves Abraxane nab-paclitaxel as first-line treatment of metastatic pancreatic cancer in combination with gemcitabine

Celgene Corp. (NASDAQ:CELG)

FDA approves Otezla apremilast to treat adults with active psoriatic arthritis

Celltrion Inc. (KOSDAQ:068279)

South Korea approves Herzuma trastuzumab, a biosimilar of Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit, to treat early and advanced HER2-positive breast cancer and advanced stomach cancer

Celltrion Inc. (KOSDAQ:068279)/Hospira Inc. (NYSE:HSP)

Canada approves Inflectra/Remsima infliximab to treat rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis and psoriasis. The product is a biosimilar of Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK)

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP)

FDA grants accelerated approval to Northera droxidopa to treat neurogenic orthostatic hypotension (NOH)

Daiichi Sankyo Co. Ltd. (Tokyo:4568)/Eli Lilly and Co. (NYSE:LLY)

Japan approves Efient prasugrel to treat patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI)

Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506)/Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)

EC approves Latuda lurasidone to treat schizophrenia in adults

Endo International plc (NASDAQ:ENDP; TSX:ENL)/Bayer AG (Xetra:BAYN)

FDA approves Aveed testosterone to treat male hypogonadism

Exelixis Inc. (NASDAQ:EXEL)

EC grants conditional approval for Cometriq cabozantinib to treat progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC)

Gilead Sciences Inc. (NASDAQ:GILD)

EC approves Sovaldi sofosbuvir to treat chronic HCV in adults, including patients co-infected with HIV

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

EC approves Eperzan albiglutide to treat Type II diabetes as monotherapy or as add-on therapy

Japan Tobacco Inc. (Tokyo:2914)/

FDA grants accelerated approval for Mekinist trametinib in combination with Tafinlar dabrafenib